Takeda Pharmaceuticals Korea is approved for its crohn’s disease treatment, ‘Kinteles Inj.’ from the Ministry of Health and Welfare

Takeda Pharmaceuticals Korea (President Choon-yup Lee) announced that it has acquired an approval for its ulcerative colitis(UC) and crohn’s disease(CD) treatment, Kinteles Inj. (generic name: vedolizumab), from the Ministry of Food and Drug Safety.

Kinteles Inj., a treatment for adults with moderate to severe UC and CD, is used for patients who does not show any reaction, show less and less r...